SCHEMBL30477884

SCHEMBL30477884

Cc1c(-c2ccccc2)cccc1N1CCC(NC2CCC(C(=O)O)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 7/20 0.56
PDCD1 Q15116 5/20 0.56
VCP P55072 1/20 0.47
CYP46A1 Q9Y6A2 3/20 0.43
NOTUM Q6P988 3/20 0.40
MAPT P10636 2/20 0.39
APAF1 O14727 1/20 0.39
NSD2 O96028 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
CASP3 P42574 1/20 0.39
RECQL P46063 1/20 0.39
GALK1 P51570 1/20 0.39
KMT2A Q03164 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19640681 1.00 CD274 (0.56) CD274PDCD1VCPCYP46A1NOTUM
SCHEMBL30477890 0.93 CD274 (0.56) CD274PDCD1VCPCYP46A1NOTUM
SCHEMBL19640628 0.93 CD274 (0.56) CD274PDCD1VCPCYP46A1NOTUM
SCHEMBL19640613 0.90 PDCD1 (0.55) CD274PDCD1VCPCYP46A1MAPT
SCHEMBL30477888 0.90 PDCD1 (0.55) CD274PDCD1VCPCYP46A1MAPT
SCHEMBL19640655 0.89 CD274 (0.52) CD274PDCD1VCPCYP46A1NOTUM
SCHEMBL19640609 0.87 CD274 (0.53) CD274PDCD1VCPCYP46A1MAPT
SCHEMBL19640563 0.87 CD274 (0.53) CD274PDCD1VCPCYP46A1MAPT
SCHEMBL19640562 0.87 CD274 (0.53) CD274PDCD1VCPCYP46A1MAPT
SCHEMBL24041222 0.85 CD274 (0.53) CD274PDCD1VCPMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673883-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673883-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS CD274 88/4885PDCD1 157/4885VCP 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.